Mosley, Terrance
Khaketla, Moliehi
Armstrong, Heather L.
Cui, Zishan
Sereda, Paul
Lachowsky, Nathan J.
Hull, Mark W.
Olarewaju, Gbolahan
Jollimore, Jody
Edward, Joshua
Montaner, Julio S. G.
Hogg, Robert S.
Roth, Eric A.
Moore, David M.
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA031055-01A1)
Canadian Institutes of Health Research (MOP-107544)
Canadian Foundation for AIDS Research
National Institutes of Health (R01DA036307)
AbbVie
Bristol-Myers Squibb
Gilead Sciences
Janssen Pharmaceuticals
Merck
ViiV Healthcare
Michael Smith Foundation for Health Research (5209)
Article History
First Online: 17 January 2018
Compliance with Ethical Standards
:
: NJL was supported by a CANFAR/CTN Postdoctoral Fellowship Award. JSGM is supported with grants paid to his institution by the British Columbia Ministry of Health and by the US National Institutes of Health (R01DA036307). JSGM has also received limited unrestricted funding, paid to his institution, from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. DMM and NJL are supported by Scholar Award from the Michael Smith Foundation for Health Research (#5209, #16863). HLA is supported by a Postdoctoral Fellowship Award from the Canadian Institutes of Health Research (Grant # MFE-152443).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.